AstraZeneca
AZN · Pharmaceuticals
$171.49
0.6%Pfizer
PFE · Pharmaceuticals
$30.03
1.3%The short version
- Pfizer is the larger business, with $62.6B of revenue in fiscal 2025 against $58.7B for AstraZeneca.
- AstraZeneca grew revenue faster (8.6%, against −1.7%).
- AstraZeneca turned more of its sales into free cash flow (20.0% FCF margin, against 14.5% FCF margin).
- AstraZeneca earned a higher return on the capital invested in it (16.8%, against 7.3%).
| Latest fiscal year | AZN · FY25 | PFE · FY25 |
|---|---|---|
| Size | ||
| Market cap | $267.9B | $171.1B |
| Revenue | $58.7B | $62.6B |
| Free cash flow | $11.8B | $9.1B |
| Net income | $10.2B | $7.8B |
| Growth | ||
| Revenue growth | 8.6% | −1.7% |
| 5-year growth | 17.2% | 8.5% |
| Share count change | −0.1% | 0.2% |
| Profitability | ||
| Gross margin | 81.9% | 74.3% |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 12.4% |
| FCF margin | 20.0% | 14.5% |
| Return on capital | 16.8% | 7.3% |
| Return on equity | 22.9% | 8.9% |
| Balance sheet | ||
| Net debt | $22.1B | $54.3B |
| Net debt / EBITDA | — | 3.2x |
| Dividends and buybacks | $5.5B | $9.8B |
| Valuation & quality | ||
| P/E | — | 39.5x |
| Piotroski F-score | 9 | 6 |
FY16
AZN $23.0B
PFE $52.8B
FY17
AZN $22.5B
PFE $52.5B
FY18
AZN $22.1B
PFE $40.8B
FY19
AZN $24.4B
PFE $40.9B
FY20
AZN $26.6B
PFE $41.7B
FY21
AZN $37.4B
PFE $81.3B
FY22
AZN $44.4B
PFE $101.2B
FY23
AZN $45.8B
PFE $59.6B
FY24
AZN $54.1B
PFE $63.6B
FY25
AZN $58.7B
PFE $62.6B
AZN
PFE
FY16
AZN 21.3%
PFE —
FY17
AZN 16.4%
PFE —
FY18
AZN 15.3%
PFE —
FY19
AZN 12.0%
PFE —
FY20
AZN 19.4%
PFE —
FY21
AZN 2.8%
PFE —
FY22
AZN 8.5%
PFE —
FY23
AZN 17.9%
PFE —
FY24
AZN 18.5%
PFE —
FY25
AZN 23.4%
PFE —
AZN
PFE
FY16
AZN $2.7B
PFE $14.4B
FY17
AZN $2.3B
PFE $14.8B
FY18
AZN $1.6B
PFE $13.8B
FY19
AZN $2.0B
PFE $10.5B
FY20
AZN $3.8B
PFE $12.2B
FY21
AZN $4.9B
PFE $29.9B
FY22
AZN $8.7B
PFE $26.0B
FY23
AZN $9.0B
PFE $4.8B
FY24
AZN $9.9B
PFE $9.8B
FY25
AZN $11.8B
PFE $9.1B
AZN
PFE
FY16
AZN 17.3%
PFE 11.0%
FY17
AZN 12.8%
PFE 15.6%
FY18
AZN 11.8%
PFE 5.4%
FY19
AZN 8.7%
PFE 12.8%
FY20
AZN 15.6%
PFE 9.9%
FY21
AZN 1.9%
PFE 32.0%
FY22
AZN 6.2%
PFE 32.0%
FY23
AZN 11.8%
PFE 2.5%
FY24
AZN 13.0%
PFE 7.6%
FY25
AZN 16.8%
PFE 7.3%
AZN
PFE
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.